专家组成员 Selphi 专家组 诊断与分期架构 临床决策主要因素 多团队潜在偏差 肿瘤消融方案 疾病控制方案 外科治疗 肝切除适应症 围手术期全身治疗 局部治疗全身治疗
返回首页
  • [全身治疗] EASL 2025 肝癌的全身治疗 日期:2026-08-10 16:37:19 点击:99

    Recommendation In patients with advanced HCC. preserved liver function (Child-Pugh A) and ECOG performance status 0-1, combinations including at least one PD-1 or PD-L1 inhibitor should be offered, provided there are no contraindications (...

  • 11条记录
推荐内容